Dragonfly Therapeutics Announces New Multi-Target Collaboration with Merck to Use Dragonfly's Proprietary TriNKET™ Platform to Develop Novel Drug Candidates for Patients with Solid Tumors

Merck receives exclusive options to license a number of Dragonfly's candidate natural killer (NK) cell engager immunotherapies for solid tumor malignancies.  WALTHAM, Massachusetts, Oct. 1, 2018 /PRNewswire/ -- Dragonfly Therapeutics, Inc. ("Dragonfly"), today announced a strategi...

from PR Newswire: //https://ift.tt/2xMzPoc